hidden pixel

5-apdb Information

5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB, 3-Desoxy-MDA, EMA-4) is a putative entactogen drug of the phenethylamine and amphetamine classes.[1] It is an analogue of the MDA where the heterocyclic 3-position oxygen from the 3,4-methylenedioxy ring has been replaced by a methylene group.[1] 6-APDB is an anlogue of 5-APDB where the 4-position oxygen has been replaced by a methylene instead.[1] 5-APDB was developed by a team led by David E. Nichols at Purdue University as part of their research into non-neurotoxic analogues of MDMA.[1]

In animal studies, 5-APDB's effects generalize most closely to non-stimulant MDMA analogues such as MBDB and MMAI, while producing no substitution for LSD or amphetamine.[1] In vitro studies show that 5-APDB acts as a highly selective serotonin releasing agent (SSRA), with IC50 values of 130 nM, 7,089 nM, and 3,238 nM for inhibiting the reuptake of serotonin, dopamine, and norepinephrine, respectively.[1] In contrast, 6-APDB is more balanced on the three monoamine neurotransmitters and acts more similarly to MDA and MDMA.[1] Anecdotal reports from human users suggest that 5-APDB produces mild empathy but with relatively little euphoria and is accompanied by sedation.

Methoxy-substituted analogues of 5-APDB and 6-APDB have also been made and substituted for DOM in animal tests, although they were around 10x less potent than DOM.[2][3]

See also

References

  1. ^ a b c d e f g Monte AP, Marona-Lewicka D, Cozzi NV, Nichols DE (November 1993). "Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogues of 3,4-(methylenedioxy)amphetamine". Journal of Medicinal Chemistry 36 (23): 3700–6. doi:10.1021/jm00075a027. PMID 8246240.
  2. ^ Nichols, DE; Hoffman, AJ; Oberlender, RA; Riggs, RM (1986). "Synthesis and evaluation of 2,3-dihydrobenzofuran analogues of the hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane: drug discrimination studies in rats.". Journal of medicinal chemistry 29 (2): 302–4. doi:10.1021/jm00152a022. PMID 3950910.
  3. ^ Nichols, DE; Snyder, SE; Oberlender, R; Johnson, MP; Huang, XM (1991). "2,3-Dihydrobenzofuran analogues of hallucinogenic phenethylamines.". Journal of medicinal chemistry 34 (1): 276–81. doi:10.1021/jm00105a043. PMID 1992127.
Entactogens
Phenylalkylamines
Cyclized phenyl- alkylamines
Tryptamines
Others Naphthylisopropylamine
Hallucinogens
Psychedelics 5-HT2AR agonists
Dissociatives NMDAR antagonists
Deliriants mAChR antagonists
Miscellaneous
Cannabinoids CB1R agonists
D2R agonists * Also indirect D2 agonists such as dopamine reuptake inhibitors (cocaine, methylphenidate), releasing agents (amphetamine, methamphetamine), and precursors (levodopa).
GABAAR agonists
Inhalants Mixed MOA
κOR agonists
σR agonists
Others
Serotonergics
5-HT1 receptor ligands
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2 receptor ligands
5-HT2A
5-HT2B
5-HT2C
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Reuptake inhibitors
SERT
VMAT
Releasing agents
Enzyme inhibitors
Anabolism
TPH
AAAD
Catabolism
MAO
Others
Precursors
Cofactors
Others
Phenethylamines
Phenethylamines
Amphetamines Phenylisopropylamines
Phentermines
Cathinones
Phenylisobutylamines
Phenylalkylpyrrolidines
Catecholamines (and close relatives)
Miscellaneous

Categories:

 

The above information uses material from Wikipedia and is licensed under the GNU Free Documentation License.
Some facts may not have been fully verified for accuracy. [Disclaimers]
This page was last archived by our server on Fri May 18 08:57:18 2012.
Displaying this page or its contents does not use any Wikimedia Foundation's resources.
The owners of this site proudly support the Wikimedia Foundation.